Evidence map›Paper›PMID 38334001›Full record

ArticleHypertension (Dallas, Tex. : 1979)2024

Circulating Dipeptidyl Peptidase 3 Modulates Systemic and Renal Hemodynamics Through Cleavage of Angiotensin Peptides.

Adrien Picod, Sandrine Placier, Magali Genest, Jacques Callebert, Nathan Julian, Maxime Zalc, Noma Assad, Hugo Nordin, Karine Santos, Stéphane Gaudry and 3 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Hypertension (Dallas, Tex. : 1979), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Influence of adrenomedullin on the enzymatic activity of dipeptidyl peptidase 3Journal of enzyme inhibition and medicinal chemistry · 2026
    Article
  5. Article
  6. Kidney Failure in Cardiogenic Shock.Circulation. Heart failure · 2026
    Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 3 countries.

Adrien PicodInstitut National de la Santé et de la Recherche Médicale UMR-S 942 MASCOT - Paris - Cité University, Paris, France (A.P., M.G., J.C., N.J., M.Z., N.A., H.N., A.M., F.A.).ORCID 0000-0002-0639-5598
Sandrine Placier *INSERM UMR-S 1155 CORAKID - Paris - Sorbonne University, France (S.P., S.G., C.C.).
Magali Genest *Institut National de la Santé et de la Recherche Médicale UMR-S 942 MASCOT - Paris - Cité University, Paris, France (A.P., M.G., J.C., N.J., M.Z., N.A., H.N., A.M., F.A.).
Jacques CallebertInstitut National de la Santé et de la Recherche Médicale UMR-S 942 MASCOT - Paris - Cité University, Paris, France (A.P., M.G., J.C., N.J., M.Z., N.A., H.N., A.M., F.A.).ORCID 0000-0002-5622-851X
Nathan JulianInstitut National de la Santé et de la Recherche Médicale UMR-S 942 MASCOT - Paris - Cité University, Paris, France (A.P., M.G., J.C., N.J., M.Z., N.A., H.N., A.M., F.A.).ORCID 0000-0003-4144-7549
Maxime ZalcInstitut National de la Santé et de la Recherche Médicale UMR-S 942 MASCOT - Paris - Cité University, Paris, France (A.P., M.G., J.C., N.J., M.Z., N.A., H.N., A.M., F.A.).ORCID 0000-0001-7284-7030
Noma AssadInstitut National de la Santé et de la Recherche Médicale UMR-S 942 MASCOT - Paris - Cité University, Paris, France (A.P., M.G., J.C., N.J., M.Z., N.A., H.N., A.M., F.A.).
Hugo NordinInstitut National de la Santé et de la Recherche Médicale UMR-S 942 MASCOT - Paris - Cité University, Paris, France (A.P., M.G., J.C., N.J., M.Z., N.A., H.N., A.M., F.A.).
Karine Santos4TEEN4 Pharmaceuticals Gmbh, Hennigsdorf, Germany (K.S.).ORCID 0000-0003-0467-7708
Stéphane GaudryINSERM UMR-S 1155 CORAKID - Paris - Sorbonne University, France (S.P., S.G., C.C.).
Christos ChatziantoniouINSERM UMR-S 1155 CORAKID - Paris - Sorbonne University, France (S.P., S.G., C.C.).
Alexandre MebazaaInstitut National de la Santé et de la Recherche Médicale UMR-S 942 MASCOT - Paris - Cité University, Paris, France (A.P., M.G., J.C., N.J., M.Z., N.A., H.N., A.M., F.A.).ORCID 0000-0001-8715-7753
Feriel AzibaniInstitut National de la Santé et de la Recherche Médicale UMR-S 942 MASCOT - Paris - Cité University, Paris, France (A.P., M.G., J.C., N.J., M.Z., N.A., H.N., A.M., F.A.).
Anna Needs Neuroblastoma Answers · USAssistance Publique – Hôpitaux de Paris · FRInserm · FRHenkel (Germany) · DEUniversité Paris-Est Créteil · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHigh circulating DPP3 (dipeptidyl peptidase 3) has been associated with poor prognosis in critically ill patients with circulatory failure. In such situation, DPP3 could play a pathological role, putatively via an excessive angiotensin peptides cleavage. Our objective was to investigate the hemodynamics changes induced by DPP3 in mice and the relation between the observed effects and renin-angiotensin system modulation.

methodsTen-week-old male C57Bl/6J mice were subjected to intravenous injection of purified human DPP3 or an anti-DPP3 antibody (procizumab). Invasive blood pressure and renal blood flow were monitored throughout the experiments. Circulating angiotensin peptides and catecholamines were measured and receptor blocking experiment performed to investigate the underlying mechanisms.

resultsDPP3 administration significantly increased renal blood flow, while blood pressure was minimally affected. Conversely, procizumab led to significantly decreased renal blood flow. Angiotensin peptides measurement and an AT1R (angiotensin II receptor type 1) blockade experiment using valsartan demonstrated that the renovascular effect induced by DPP3 is due to reduced AT1R activation

conclusionsHigh circulating DPP3 increases renal blood flow due to reduced AT1R activation via decreased concentrations of circulating angiotensin peptides while blood pressure is maintained by concomitant endogenous catecholamines release.

Indexed as

HemodynamicsPeptidesAngiotensin IIAnimalsCatecholaminesDipeptidyl-Peptidases and Tripeptidyl-PeptidasesHumansMaleMiceAngiotensin IICatecholaminesDipeptidyl-Peptidases and Tripeptidyl-PeptidasesPeptidesangiotensin IIblood pressurecatecholaminescirculatory failureDPP3 protein, humanprocizumabrenal blood flowrenin–angiotensin system

Identifiers

PMID38334001
PMCPMC10956665
OpenAlexW4391684385

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.